David A. ReardonAnnick DesjardinsJames J. VredenburghJames E. HerndonApril CoanSridharan GururanganKatherine B. PetersRoger McLendonSith SathornsumeteeJeremy N. RichEric S. LippDorothea JanneyHenry S. FriedmanDuke UniversityMahidol UniversityCleveland Clinic Foundation2018-06-112018-06-112012-10-01Cancer. Vol.118, No.19 (2012), 4759-4767109701420008543X2-s2.0-84866487544https://repository.li.mahidol.ac.th/handle/20.500.14594/13603BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratified patients into astrocytoma and oligodendroglioma cohorts. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 400 mg per day for patients not on enzyme-inducing antiepileptic drugs (EIAEDs) and at 500 mg twice a day if on EIAEDs. The primary endpoint was progression-free survival at 12 months (PFS-12) and secondary endpoints were safety, median progression-free survival, and radiographic response rate. RESULTS: Thirty-Two patients were enrolled into each cohort. Eleven patients (17%) had before radiotherapy and 24 (38%) had received before chemotherapy. The median PFS and PFS-12 were 11 months and 39%, respectively. Outcome did not differ between the histologic cohorts. No patient achieved a radiographic response. The most common grade 3 or greater adverse events were neutropenia (11%), thrombocytopenia (3%), and diarrhea (3%). CONCLUSIONS: Imatinib plus hydroxyurea was well tolerated among recurrent/progressive LGG patients but this regimen demonstrated negligible antitumor activity. © 2012 American Cancer Society.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1002/cncr.26541